Tarsus Pharmaceuticals: Leading in the Fight Against Eyelid Inflammation

The most important drug called "XDEMVY" has shown strong market development and has significantly contributed to the recent strong performance of the stock. Lotilaner is the only approved treatment for Demodex blepharitis, which demonstrates high efficacy and strong market introduction figures, achieving annual sales of $113 million. Tarsus has a robust pipeline, including promising Phase 2 studies for ocular rosacea and Lyme disease. Tarsus Pharmaceuticals (NASDAQ: TARS) is developing Lotilaner for several eye and infectious diseases....